FDA Brief

Warning letters Drugs

FDA warning letter to

Premier Nutra Pharma Inc.

High riskIssued Dec 9, 2022Posted May 9, 2023Division of Pharmaceutical Quality Operations IV

FDA cited Premier Nutra Pharma, a Carlsbad, California contract maker of nasal spray drugs, for CGMP violations after microbial contamination.

What happened

FDA inspected Premier Nutra Pharma's Carlsbad, California facility from July 5 to July 8, 2022 and found the company did not follow CGMP (current good manufacturing practice, the FDA's required quality rules for drug manufacturing). A nasal spray batch was contaminated with yeast and reached the market; the customer recalled it. An ingredient used in several products was visibly contaminated with bees and/or yeast but was still used, and the firm had no cleaning procedures, no environmental monitoring and no batch records.

What FDA found

  1. The firm did not investigate microbial contamination of a nasal spray batch, nor check whether other batches were similarly contaminated, even though an ingredient used in several products was visibly contaminated with bees and/or yeast.

    21 CFR 211.192
  2. The firm had no written procedures to prevent microbial contamination: no environmental monitoring, no microbiological testing of facilities or equipment, and no cleaning procedures or records.

    21 CFR 211.113(a)
  3. The firm did not test each batch of drug product to show it was free of objectionable microorganisms.

    21 CFR 211.165(b)
  4. The firm had no batch production and control records for its formulation, filling and packaging operations, so it could not show its products were the same from batch to batch.

    21 CFR 211.188
  5. The firm had no quality unit (the independent group that reviews and releases batches) and no written procedures for its duties, such as batch record review, annual product review, deviations, corrective actions, complaints, retain samples and recalls.

    21 CFR 211.22(a) and 211.22(d)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with independent assessments of its investigations and manufacturing operations, a microbiological risk assessment, test results for retained batches, and corrective action plans. The firm must also notify FDA before resuming drug manufacturing, since it told FDA it had stopped production.

Who should pay attention

  • brands that contract-manufacture OTC nasal sprays or other drugs at this firm
  • companies that buy or distribute nasal spray drug products
  • quality teams at contract manufacturers handling non-sterile drug production

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk